NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Cash Flow-to-Debt Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Cash Flow-to-Debt Ratio of -0.56x as of September 2025, meaning its operating cash flow of $-32.77 Million could theoretically repay -1% of its total liabilities ($58.36 Million) in one year. Explore NewAmsterdam Pharma Company N.V. Ordinar long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NewAmsterdam Pharma Company N.V. Ordinary Shares Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for NewAmsterdam Pharma Company N.V. Ordinary Shares across 5 annual periods. Also explore NewAmsterdam Pharma Company N.V. Ordinar assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Year-by-year debt coverage analysis for NewAmsterdam Pharma Company N.V. Ordinary Shares. For market capitalisation and broader financial context, see NewAmsterdam Pharma Company N.V. Ordinar (NAMS) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.48x | $-158.56 Million | $107.12 Million | ▲ +38.5% |
| 2023 | -2.41x | $-141.22 Million | $58.70 Million | ▼ -1192.4% |
| 2022 | 0.22x | $10.66 Million | $48.43 Million | ▲ +108.5% |
| 2021 | -2.60x | $-29.51 Million | $11.36 Million | ▼ -338.9% |
| 2020 | -0.59x | $-7.34 Million | $12.41 Million | — |